It seems that the Brits also want to use Avastin instead of Lucentis in treating AMD, and the UK’s cost-effectiveness body of NICE (the National Institute for Health and Clinical Excellence) is taking the first steps to appraise the off-label use of …
Highlights from the 2010 ASCRS Meeting and World Cornea Congress
Featured Article
Uncategorized
Technology Converts Facial Emotions into Tactile Feedback for Visually Impaired
Shafiq ur Réhman, a doctoral student at Umeå University in Sweden has unveiled his thesis project, a technology that converts facial emotions into special tactile sensations for the visually impaired. The system uses a webcam to capture …
Uncertain Times for Practices and Patients
Featured Article
Case Study: Surgical Correction of Cataract and Astigmatism
Featured Article
Avastin/Lucentis Update 37: The Controversy Continues – Genentech “Paid to Play”
As I read the news release from the NEI/NIH yesterday morning, about the one-year results of the clinical trial evaluating the combination use of Lucentis with pan-retinal laser therapy to treat diabetic macular edema, prior to posting it online, and l…